Modality
Nanobody
MOA
KIF18Ai
Target
MET
Pathway
Autophagy
IPFALLPV
Development Pipeline
Preclinical
~Feb 2014
→ ~May 2015
Phase 1
~Aug 2015
→ ~Nov 2016
Phase 2
~Feb 2017
→ ~May 2018
Phase 3
Aug 2018
→ Oct 2031
Phase 3Current
NCT03757549
1,510 pts·IPF
2018-08→2031-10·Not yet recruiting
1,510 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-10-255.6y awayPh3 Readout· IPF
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Not yet…
Catalysts
Ph3 Readout
2031-10-25 · 5.6y away
IPF
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03757549 | Phase 3 | IPF | Not yet recr... | 1510 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| BMR-8526 | BioMarin | Phase 1/2 | CD38 | |
| Bemanaritide | Blueprint Medicines | Phase 2 | CD38 |